Merck Stops Lung Cancer Study For Keytruda Combo Due To Ineffective Results, Side Effects
Portfolio Pulse from Vandana Singh
Merck & Co Inc (NYSE:MRK) has discontinued its Phase 3 KeyVibe-008 trial for a Keytruda combination due to ineffective results and higher adverse events. The trial compared the combination to Roche's Tecentriq for treating extensive-stage small cell lung cancer. Merck is notifying investigators and offering alternative treatments. The stock is up 0.82% following the announcement.
August 08, 2024 | 3:51 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Merck has stopped its Phase 3 KeyVibe-008 trial for a Keytruda combination due to ineffective results and higher adverse events. The stock is up 0.82% following the announcement.
The discontinuation of the trial could have been seen as a negative, but the stock price increased by 0.82%, indicating that investors may have already priced in the potential failure or are optimistic about other developments.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Roche's Tecentriq was the control arm in Merck's discontinued KeyVibe-008 trial. The trial's failure may indirectly benefit Roche as an alternative treatment option.
With Merck halting its trial, Roche's Tecentriq may see increased usage as an alternative treatment, potentially benefiting Roche.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50